Jounce Therapeutics Inc

NASDAQ:JNCE   3:59:47 PM EDT
6.68
-0.14 (-2.05%)
Other Pre-Announcement

Jounce Therapeutics Reports Q3 Loss Per Share $0.73

Published: 11/06/2020 12:13 GMT
Jounce Therapeutics Inc (JNCE) - Jounce Therapeutics Reports Third Quarter 2020 Financial Results.
Q3 Loss per Share $0.73.
Q3 Earnings per Share Estimate $-0.47 -- Refinitiv Ibes Data (analyst estimates).
On Track to Begin Enrollment in Phase 1 Trial for Jtx-8064 by Year-end 2020.
Jounce Therapeutics - Expects Investments, Proceeds From Gilead, to Be Sufficient to Enable Funding of Capital Expenditure Requirements Into 2023.